Latest News

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News